BCR and chronic myelogenous leukemia, BCR-ABL1 positive: A promising target recognition concept was recently reported with the intention of addressing this fundamental problem,44 and, if proven successful, it could substantially reduce, or even eliminate, undesired off‐target effects.37 In the context of CML, the concept may facilitate specific BCR‐ABL1 mRNA recognition, and hence selective therapeutic intervention, exclusively in CML cells.